{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.5","upperLimit":"7.1","value":"5.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"description":"PFS was defined as those who progress or die without progression as failures, and censoring those who do not. Progressive disease was assessed by the 2016 International Myeloma Working Group (IMWG) response criteria and is an increase of 25% from lowest confirmed response value in one or more of the following criteria: Serum M-protein (absolute increase must be ≥0·5 g/dL); Serum M-protein increase ≥1 g/dL, if the lowest M component was ≥5 g/dL; Urine M-protein (absolute increase must be ≥200 mg/24 h); In patients without measurable serum and urine M-protein levels, the difference between involved and uninvolved free light chain (FLC) levels (absolute increase must be \\>10 mg/dL).","dispersionType":"95% Confidence Interval","groups":[{"description":"Avelumab 800 mg IV every two weeks in combination with radiation therapy\n\nAvelumab: Avelumab 800 mg intravenous (IV) over 60 minutes (+/- 20 minutes) on days 1 and 15 of each 28-day cycle\n\nExternal beam radiotherapy: 5 gray (Gy) per fraction will be delivered on 5 consecutive treatment days for a total dose 25 Gy","id":"OG000","title":"1/Avelumab 800 mg Intravenous (IV) Every Two Weeks in Combination With Radiation Therapy"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"End of study, an average of 11 months","title":"Progression-free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"Months"}